Viking Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
116.7M
on 2026-06-30, from 110.2M on 2024-03-31 10-Q ↗
a raise that quarter, at its price
Newest
No limit
S-3ASR of 2026-07-30. An automatic shelf: the form sets no dollar limit. 1 prospectus supplement filed under it since. S-3ASR ↗
$500.0M
Stifel, Nicolaus, agreement of 2026-07-29. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗
Warrants
The 10-Q filed 2026-07-29 is not read yet.
Cash
4.8 quarters
$501.7M on 2026-06-30 ÷ $104.6M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-09-25 | Public offering | 7,857,143 | $35.00 | $275.0M | 424B5 ↗ |
Also on file: $225.0M convertible notes, 2026-09-23 424B5 ↗ · $33.8M convertible notes, 2026-09-23 8-K ↗